Tier 3 Drug Shortages

Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:

  • a review of the information gathered on the shortage issue, and
  • a thorough discussion on its potential impact and next steps.

Below are the newest and most recently updated active ingredients that have been designated as Tier 3 shortages. Click on the active ingredient to see a list of the associated Tier 3 drug shortage and/or discontinuation reports.

Active Ingredient

23 active ingredients found

ROPIVACAINE HYDROCHLORIDE

solution

ACYCLOVIR SODIUM INJECTION

solution

ALDESLEUKIN

powder for solution

Alprostadil Sterile Solution

solution

Apomorphine Hydrochloride

solution

Apomorphine Hydrochloride

film, soluble

ASPARAGINASE - ERWINASE

powder for solution

CALCITONIN

solution

CEFAZOLIN

solution

DIGOXIN IMMUNE FAB

powder for solution

DISOPYRAMIDE

capsule

DOCETAXEL INJECTION

solution

FLUDARABINE PHOSPHATE FOR INJECTION

solution

GLUCAGON

powder for solution

IDARUBICIN HYDROCHLORIDE

solution

IPRATROPIUM BROMIDE

solution

LITHIUM CARBONATE

capsule

LITHIUM CARBONATE

tablet (extended-release)

Methotrexate

solution

PEGASPARGASE

solution

peginterferon alfa-2A injection

solution

RIFABUTIN

capsule

SALBUTAMOL

metered-dose aerosol

SALBUTAMOL

solution

SPIRONOLACTONE

tablet

VINCRISTINE SULFATE INJECTION

solution

Showing 1 to 26 of 26